吉西他滨联合顺铂一线治疗转移性三阴性乳腺癌的临床观察被引量：6

Clinical observation of the first-line therapy of gemcitabine combined with cisplatin in transitivity triple negative breast cancer

暂未订购

导出

摘要目的观察吉西他滨联合顺铂一线治疗转移性三阴性乳腺癌的近期疗效及毒副反应。方法 20例ER、PR、Her-2均为阴性的乳腺癌患者,均曾接受过蒽环类或紫杉类辅助化疗,给予吉西他滨联合顺铂方案化疗,具体用药:吉西他滨1000mg/m2,静滴30min,D1,8;顺铂25mg/m2,静滴D1～3,21d为1个周期,至少2个周期,2个周期后评价疗效和毒副反应。结果 20例患者中获CR2例(10%),PR8例(40%),SD8例(40%),PD2例(10%),总有效率达50%。主要毒副反应为骨髓抑制和消化道反应,其次有皮疹、发热、便秘。结论吉西他滨联合顺铂治疗转移性三阴乳腺癌有较好的近期疗效,毒副反应可耐受,值得临床应用及进一步推广。 Objective To observe the recent efficacy and toxic and adverse reactions of the first-line therapy of gemcitabine combined with cisplatin in transitivity triple negative breast cancer. Methods Twenty patients of breast cancer with ER, PR, Her-2 negative all received the adjuvant chemotherapy of anthracycline or taxanes, and were given the chemotherapy of gemcitabine combined with cisplatin.The specific pharmacy was as follows： gemcitabine 1 000 mg/m2, drip, 30 min, d1,8, cisplatin, 25 mg/m2, drip, d1-3, 21 days were as a course, 2 courses at least. After 2 courses, the efficacy and toxic and adverse reactions were evaluated. Results Among 20 cases, there were 2 cases （10%） of CR, 8 cases （40%） of PR, 8 cases （40%） of SD, 2 cases （10%） of PD, the total effective rate reached to 50%, the main toxic and adverse reactions were myelosuppression and vomiting, the next were skin rash, fever, constipation. Conclusion Gemcitabine combined with cisplatin in the treatment of transitivity triple negative breast cancer has good recent efficacy, the toxic and adverse reactions can tolerate, which is worthy of clinical application and further promotion.

作者陈丽萍潘平森梅华

机构地区江西省新余市人民医院肿瘤科

出处《中国当代医药》 2012年第34期84-85,共2页 China Modern Medicine

关键词吉西他滨顺铂三阴性乳腺癌化疗 Gemcitabine Cisplatin Triple negative breast cancer Chemotherapy

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献8

1Perou CM,Sorlie T,Eisen MB,et al.Molecular portraits of human breast tumors[J].Nature,2000,406(6797):747-752.
2Sotiriou C,Neo SY,McShane LM,et al.Breast cancer classification and prognosis based on gene expression profiles from a population-based study[J].Proc Natl Acad Sci,2003,100:10393-10398.
3Eneman JD,Wood ME,Muss HB.Selecting adjuvant endocrine therapy for breast cancer[J].Oncology,2004,18(14):1733-1744.
4Michaud LB.Treatment-experienced breast cancer[J].Am J Health Syst Pharm,2008,65(10 Suppl 3):4-9.
5Seidman AD.Gemcitabine as single agent therapy in the management of advanced breast cancer[J].Oncology,2001,15(Suppl 3):11-14.
6Bhattacharyya A,Ear US,Koler BH,et al.The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin[J].J Biol Chem,2000,275(31):23899.
7Van Moorsel CJ,Veeman G,Bergman AM,et al.Combination chemotherapy studies with gemcitabine[J].Semin Oncol,1997,24(2 Suppl 7):17-23.
8Achanta G,Pelicano H,Feng L,et al.Interaction of p53 and DNA-PK in response to nucleoside analogues:Potential role as a sensor complex for DNA damage[J].Cancer Res,2001,61:8723-8729.